SHR7390

SHR7390 is a novel, orally available small molecule that acts as a selective inhibitor of mitogen-activated protein kinase kinase 1 (MEK1) and mitogen-activated protein kinase kinase 2 (MEK2), also known as MAP2K or MAPK/ERK kinase. It is being developed primarily for the treatment of advanced solid tumors and has been studied both as monotherapy and in combination with camrelizumab (a PD-1 inhibitor) in clinical trials. The drug has demonstrated manageable safety profiles and preliminary antitumor activity, particularly in patients with advanced or metastatic colorectal cancer, including those with various BRAF and MSI statuses. The primary developer is Jiangsu Hengrui Medicine Co., often in collaboration with Fudan University.

Other names

MEK inhibitor SHR 7390